Tisotumab Vedotin: First Approval

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

(2021) Robert L Coleman et al.   LANCET ONCOLOGY

930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors

(2021) D. Hong et al.   ANNALS OF ONCOLOGY

Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress).

(2021) Ignace Vergote et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).

(2020) Ignace Vergote et al.   JOURNAL OF CLINICAL ONCOLOGY

882TiP InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer

(2020) S. Blank et al.   ANNALS OF ONCOLOGY

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

(2019) Johann S de Bono et al.   LANCET ONCOLOGY

SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors.

(2019) David S. Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

(2019) David S. Hong et al.   CLINICAL CANCER RESEARCH

High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates

(2015) B. E. C. G. de Goeij et al.   MOLECULAR CANCER THERAPEUTICS

An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

(2013) E. C. W. Breij et al.   CANCER RESEARCH